Updates

Alliance Pharma

August 2012

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

The shares were hit after Alliance issued an H1 trading update that said Sanofi Pasteur Canada, which manufactures bladder cancer treatment ImmuCyst and licenses it to Alliance for distribution in the UK and Ireland, has temporarily suspended production of the drug due to a plant contamination problem. The manufacturing issues have nothing to do with Alliance as it is only the marketing partner but the problem is that its rival drug, OncoTICE, will have taken its market share and regaining it will require investment and time. ImmuCyst currently generates around Â£2m gross margin a year and Alliance said full year results to 31 December 2012 will be adversely affected by Â£1m. That said, on a more positive note, Alliance has just announce ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

Globo - Signs first MNO up for Go! EnterpriseServer

Dunelm - Rain-sodden consumers buy more homewares

Alliance Pharma (December 2022)

Alliance Pharma (November 2020)

Alliance Pharma (September 2020)

Alliance Pharma (November 2019)

Alliance Pharma (May 2019)

Alliance Pharma (February 2019)

Alliance Pharma (December 2018)

Alliance Pharma - MHRA approves Diclectin for launch (July 2018)

Alliance Pharma - Looks capable of sustaining long-term growth (May 2018)

Alliance Pharma (February 2014)

Alliance Pharma (January 2014)

Alliance Pharma (October 2013)

Alliance Pharma (July 2013)

Alliance Pharma - 50% of sales from high margin â€œdevicesâ€ (May 2013)

Alliance Pharma - Stronger than anticipated margins (February 2013)

Alliance Pharma - Toxicology product about to enter "on year" (November 2012)

Alliance Pharma - Ex-Deltacortril sales grow 13% (June 2012)

Alliance Pharma (February 2012)

Alliance Pharma (October 2011)

Alliance Pharma (August 2011)

Alliance Pharma (July 2011)

Alliance Pharma (June 2011)

Alliance Pharma (April 2011)

Alliance Pharma (February 2011)

Alliance Pharma - Very strong free cashflow (October 2010)

Alliance Pharma (June 2010)

Alliance Pharma - Broker sets 42p price target (May 2010)

Alliance Pharma - Portfolio of 53 mini cash cows (March 2010)

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X